AIM
IBRX icon

Aigen Investment Management’s ImmunityBio IBRX Stock Holding History

Aigen Investment Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-14,841
Closed -$93.8K – 855
2024
Q2 		$93.8K Sell
14,841
-1,290
-8% -$8.51K 0.02% 706
2024
Q1 		$86.6K Buy
+16,131
New +$73K 0.02% 616
2020
Q3 		– Sell
-36,261
Closed -$445K – 972
2020
Q2 		$445K Buy
+36,261
New +$205K 0.06% 502

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Aigen Investment Management's IBRX Position: Q3 2024 in Review

Aigen Investment Management sold out of ImmunityBio (IBRX) in Q3 2024, closing a stake of 14,841 shares — an estimated $93.8K sold.

Aigen Investment Management first reported a position in IBRX in Q2 2020 and held it in 3 quarters. The position peaked at $445K in Q2 2020. 181 funds tracked by Wall St. Rank hold IBRX as of Q3 2024.

  • Aigen Investment Management reported no remaining ImmunityBio position as of Q3 2024 after selling out during the quarter.
  • Aigen Investment Management sold 14,841 ImmunityBio shares in Q3 2024, an estimated $93.8K.
  • Aigen Investment Management first reported a position in ImmunityBio in Q2 2020 and held it in 3 quarters.
  • Aigen Investment Management's ImmunityBio position peaked at $445K in Q2 2020.
  • 181 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2024.

Based on Aigen Investment Management's 13F filing for Q3 2024, filed 5 Nov 2024.